International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationAn Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation Interactions
Introduction
Combining hormonal manipulation with radiotherapy for patients with clinically localized intermediate- and/or high-risk prostate cancer has become a standard of care on the basis of the results from multiple prospective randomized trials 1, 2, 3, 4. Four Phase III randomized trials used short-term neoadjuvant hormonal therapy (NHT) in combination with external beam radiotherapy (RT), and all demonstrated an improvement in either overall survival (OS) or freedom from prostate-specific antigen (PSA) failure 2, 5, 6, 7. In three of these studies, only the prostate was irradiated 5, 6, 7. To date, all the studies using long-term hormonal therapy for high-risk disease incorporated whole pelvic (WP) RT 1, 3, 4. However, some investigators believe it is not necessary to treat the pelvic lymph nodes, either because they believe that lymph node disease is tantamount to distant metastasis or, potentially, that hormonal manipulation will address microscopically involved lymph nodes, because it appears to help prevent and/or treat potential microscopic distant metastasis.
In addition to the scope of the radiation required, the question of timing of androgen suppression remains. Is NHT better or worse than adjuvant hormonal therapy (AHT) or are they equivalent?
The Radiation Therapy Oncology Group (RTOG) study 94-13 was designed to answer both questions. This trial was a multicenter prospective randomized trial designed to answer the questions concerning the value of prophylactic whole pelvic radiotherapy (WPRT) in patients who had an assessed risk of lymph node involvement of >15% (Roach formula) (8). It was also designed to answer the question of the timing of hormonal therapy (neoadjuvant vs. adjuvant) on progression-free survival (PFS). This analysis is an update of the results of RTOG 94-13 with specific focus on the unexpected interaction between field size and the timing of hormonal therapy.
Section snippets
Eligibility
Patients eligible for this trial included those with histologically confirmed, clinically localized adenocarcinoma of the prostate with an elevated PSA level of ≤100 ng/mL. Patients were stratified by T stage (T1c-T2a vs. T1b-T2b vs. T2c-T4), PSA level (<30 vs. ≥30 ng/mL), and Gleason score (<7 vs. 7–10). PSA stratification was determined from the median PSA level observed in an earlier high-risk patient study 9, 10. Additionally, eligible patients were required to have an estimated risk of
Results
This study was activated April 1, 1995, and closed June 1, 1999, with a total of 1,323 patients accrued. Of the 1,323 patients, 1,292 (98%) were considered eligible and properly entered into the study. The pretreatment characteristics of the patients are summarized in Table 1. The median age was 70 years, and nearly 23% were of African-American descent. The median PSA level was 22.6 ng/mL, and two-thirds of the patients had clinical disease Stage T2c–T4, with 73% having a Gleason score of ≥7.
Discussion
Questions regarding the timing of hormonal therapy, as well as radiation field size, in patients with adenocarcinoma of the prostate with a risk of lymph node involvement of >15% were the primary goals of this study. PFS (Fig. 1) showed that no difference resulted in PFS according to the timing of hormonal therapy. Figure 2 showed that no difference resulted in PFS by radiation field size. However, a lack of a benefit for WPRT vs. PORT or AHT vs. NHT in this group of patients was not likely to
References (24)
- et al.
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long term results of phase III RTOG 85-31
Int J Radiat Oncol Biol Phys
(2005) - et al.
Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
Int J Radiat Oncol Biol Phys
(2001) - et al.
Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study, a phase III randomized trial)
Lancet
(2002) - et al.
Ten year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
Proc ASTRO
(2006) - et al.
Short term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial
Lancet
(2005) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
J Urol
(1993)- et al.
Predicting long term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials
Int J Radiat Oncol Biol Phys
(2000) - et al.
The role of the urethrogram during simulation for localized prostate cancer
Int J Radiat Oncol Biol Phys
(1993) - et al.
Toxicity criteria of the RTOG and EORTC
Int J Radiat Oncol Biol Phys
(1995) - et al.
Practical application of biochemical failure definitions: What to do and when to do it
Int J Radiat Oncol Biol Phys
(2002)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference
Int J Radiat Oncol Biol Phys
Considerations for monitoring and evaluating treatment effects in clinical trials
Control Clin Trials
Cited by (0)
Conflict of interest: none.